[ad_1]
Elías Mosialos mentions two versions that his deputy commander headed “Θριασίου»During intubation. What the president of the Vaccination Committee said in response to a question from iEidiseis.
In the reports referring to the Subcomandante of “Θριασίου, Who is intubated at the General Hospital of the State of Nice, responds Elijah Mosialos, through its publication.
According to the LSE health policy professor, “the commander did not have any underlying disease and showed symptoms of lower respiratory tract infection last Wednesday. He underwent a coronavirus test that came back negative and showed no symptoms. On New Year’s Eve, his His health deteriorated and on New Year’s Eve he was intubated. “
“His deteriorating health is not linked to his vaccination last Sunday, as several claim,” he explained.
“But what happened here? Two versions:
- The onset of infection may have preceded vaccination.
- Get sick in the first few days after getting the vaccine. “If someone gets sick in the first few days after being vaccinated, it does not mean that the vaccine failed or that they ‘caught the virus’ by receiving the vaccine.”
Furthermore, “the immunoprotection of the vaccine begins some time after the first dose, but is not complete.” We need the second dose of the vaccine and at least 1 week after the second dose to achieve complete immunization against the virus ”, explains Mr. Mosialos, adding the following data:
“With regard to the Pfizer vaccine, the studies show that protection begins 12 days after the first dose. For the Moderna vaccine the studies show significant immunoprotection at 14 days and for the AstraZeneca vaccine at 21 days.
Furthermore, published studies on these three vaccines give us the efficacy and corresponding confidence intervals for each clinical trial:
- Pfizer: The efficacy of the vaccine is 95% (95% confidence interval: 90.3 -97.6).
- Modern: The efficacy of the vaccine is 94.1% (95% confidence interval 89.3 to 96.8%).
- AstraZeneca: 14 days after the second dose, the overall efficacy is 70 · 4% (95% confidence interval: 54 · 8 – 80 · 6). For the group that had received 2 standard doses, the efficacy was 62.1% (with 95% confidence interval: 41.0 – 75.7) while for the group that had received a first low dose and a second standard dose, efficacy was recorded as 90% (with 95% confidence interval: 67 · 4 -97 · 0). Here are some technical details about the Oxford / AstraZeneca clinical trial.
What does the published data show?
The clinical trial was originally scheduled in a single dose, but a booster dose was added when scientists realized it would likely increase efficacy. Therefore, some volunteers took the second dose months after the start of the trial, and the interval was different according to the age group, and there was the problem of the different doses. The reported efficacy results indicate an efficacy of .60% for the group that received 2 standard doses and ~ 90% for the group that initially received half and then the standard dose of the vaccine.
What is less clear is whether these differences are due to the lowest first dose, the younger participants, or the longer intervals between doses. The efficacy of the vaccine between the ages of 18 to 55 years was 59% for the standard 2-dose regimen, compared with 90% for those who received half and then the standard dose. Differences in the intervals do not appear to affect efficiency in this analysis. Is this due to the dose or the time difference between the two doses? We do not know yet. “
«What do these mean?
And after the second dose, a small percentage of those vaccinated will not have immunoprotection. However, you have to be careful in the interval between the two doses and for some time afterwards ”, concluded the professor.
{https://www.facebook.com/i.mos2020/posts/3646830265356233}
What Theodoridou said in response to iEidiseis
A relevant question from iEidiseis about the above case was answered by the president of the National Vaccination Committee, Ms. Maria Theodoridou, in the context of tonight’s briefing at the Ministry. Health:
“First I start by wishing the person who passes in the intensive care unit. There was a temporal correlation, that is, vaccination and at 3 days the appearance of this acute respiratory failure, which imposed although scientifically we could not find a correlation between the vaccination and the clinical picture of the patient in the file, in the famous yellow card that everyone should “Citizens and doctors know that there is a record of any serious event that occurs after a vaccine, as well as after taking a medicine “.
He also pointed out that “the laboratory, the outpatient examination that has been performed excludes Covid infection. “There have been more than 4 tests that were negative, so the patient was not in a period of ongoing Covid infection.”
“However, from history and development, this patient was found to have an underlying problem, which created this condition,” he added.
Finally, “the incident has been reported via yellow card to the OAS, where pharmacovigilance operates, and a special committee always evaluates what is sent after vaccines and medications and reports when the investigation of the incident is completed,” according to Ms. Theodoridou . .
[ad_2]
